The Supreme Court unanimously rejected Amarin Pharma’s induced-infringement claim against Hikma Pharmaceuticals, clarifying that a generic drugmaker’s knowledge of possible infringing use is not enough without active steps encouraging infringement.
Generic drugs can dramatically reduce prescription costs, but the path from a patented brand-name drug to a lower-cost generic is not always simple.
A 2026 Supreme Court case involving Amarin Pharma and Hikma Pharmaceuticals examined one of the most important questions in modern pharmaceutical patent law: when can a generic drug manufacturer be held liable for encouraging doctors to use its product for a purpose that is still protected by a patent?
In this Business Law 101 episode, Dr. David D. Schein explains the dispute and the Supreme Court’s unanimous conclusion that Amarin had not plausibly alleged the active steps required to support a claim of induced patent infringement.
When a pharmaceutical company develops a new drug, patents can protect the invention and specific uses of that drug for a limited period. Those rights give the patent owner an opportunity to recover research and development costs without immediate generic competition.
Once relevant patent protection expires or no longer blocks a particular use, other manufacturers may seek FDA approval to sell generic versions containing the same active ingredient.
Generic competition can significantly reduce prices because multiple manufacturers may then compete to supply the same medication.
Amarin developed Vascepa, whose active ingredient is icosapent ethyl.
The FDA first approved the drug for treatment of very high triglyceride levels. Later, the FDA approved an additional cardiovascular-risk indication for certain patients already taking statins.
Those different approved uses became important because patent protection did not necessarily apply in the same way to every use of the same drug.
A generic manufacturer may sometimes seek approval for only the unpatented uses of a brand-name drug while leaving a still-patented use off its label.
This practice is commonly known as a skinny label.
The basic idea is to allow legitimate generic competition for uses that are no longer protected without authorizing the generic manufacturer to market the product for a use that remains patented.
In this dispute, Hikma sought approval for generic icosapent ethyl while carving out Amarin’s patented cardiovascular indication.
Amarin argued that Hikma’s conduct went beyond merely selling a generic drug for an unpatented use.
The company claimed that Hikma’s labeling, public statements, and other communications encouraged healthcare providers to use the generic product for Amarin’s patented cardiovascular indication.
That theory relied on induced patent infringement.
Inducement is different from direct infringement. A company can be liable for inducing infringement when it takes active steps to encourage another person to engage in conduct that infringes a patent.
The Supreme Court unanimously concluded that Amarin’s allegations were not enough to state a plausible claim that Hikma had actively induced infringement.
The key distinction was between knowing that infringement may occur and actively encouraging it.
A generic manufacturer may understand that doctors or pharmacists could prescribe or substitute its product in ways that implicate a patented use. But knowledge alone does not automatically establish induced infringement.
The plaintiff must plausibly allege affirmative conduct showing that the defendant encouraged the infringing use.
If generic manufacturers could face inducement liability merely because they knew some doctors might prescribe their products for patented uses, the risk of litigation could make skinny-label launches much more difficult.
The Supreme Court’s ruling therefore provides greater clarity for generic manufacturers that carefully exclude patented indications from their approved labels.
At the same time, the decision does not give generic manufacturers permission to deliberately promote an infringing use. Active encouragement can still create liability when the legal requirements are satisfied.
Pharmaceutical patent law becomes especially complicated because the manufacturer does not control every prescribing or substitution decision.
A generic company may market a drug for an unpatented indication, while a physician may independently decide that the same product is appropriate for another use. State substitution laws can also allow pharmacists to dispense a generic alternative when a brand-name drug is prescribed.
That means courts must distinguish between ordinary market realities and conduct that actually encourages infringement.
No.
A patent covering a specific medical use can still be enforceable. The Supreme Court’s ruling concerns what must be alleged to hold another company responsible for inducing infringement of that patent.
The case does not eliminate use patents or prevent a patent owner from pursuing claims when there is sufficient evidence of active inducement.
The principle reaches beyond prescription drugs.
Induced infringement can arise whenever a business sells a product or service that customers may use in a way that infringes another party’s patent.
The case reinforces an important distinction for businesses:
Awareness of a customer’s possible infringing use is not necessarily the same as actively encouraging that use.
Companies developing product instructions, marketing materials, technical documentation, and sales campaigns should understand that those communications can become evidence in an inducement case.
The conflict between Amarin and Hikma illustrates the difficult balance between intellectual-property protection and market competition.
Patents are designed to reward innovation. Generic-drug laws are designed in part to make lower-cost medicines available when lawful competition becomes possible.
The Supreme Court’s unanimous ruling clarifies that a generic manufacturer using a skinny label is not automatically liable simply because some customers may use its product for a patented indication.
To plead induced infringement, the patent owner must point to active conduct encouraging that infringing use.
That is the practical lesson: knowledge and inducement are not the same thing.
Legal disclaimer: This article is for informational and educational purposes only. It is not legal, medical, pharmaceutical, or investment advice.
Explore more Business Law 101 and Supreme Court analysis at DrDaveSavesAmerica.com.
© Copyright 2026 Claremont Management Group, Inc. All Rights Reserved. No copyright asserted over US Government material or the copyrighted material of others.
